Abstract

This IAA will support the development of neutralization assays based on recombinant VSV constructs containing the Filovirus glycoprotein to assess vaccine efficacy, as well as support the identification of Zaire-Ebola virus neutralizing epitopes as surrogate markers of vaccine efficacy to the other genera of the Filoviridae.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
NIH Inter-Agency Agreements (Y01)
Project #
AAI12034001-1-0-1
Application #
8672527
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2013
Total Cost
$257,740
Indirect Cost

  Institution

Name
National Institute of Allergy and Infectious Diseases
Department
Type
DUNS #
City
State
Country
Zip Code